136 related articles for article (PubMed ID: 35923471)
1. Identification of a Rare
Lin Y; Lei Y; Li L; Su X; Tian Q; Wu W
Onco Targets Ther; 2022; 15():831-836. PubMed ID: 35923471
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report.
Shu Y; Li H; Shang H; Chen J; Su X; Le W; Lei Y; Tao L; Zou C; Wu W
Onco Targets Ther; 2020; 13():10387-10391. PubMed ID: 33116618
[TBL] [Abstract][Full Text] [Related]
3. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.
Liu Y; Liu T; Li N; Wang T; Pu Y; Lin R
Lung Cancer; 2019 Mar; 129():92-94. PubMed ID: 30797499
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with
Shu Y; Wang Z; Shang H; Le W; Lei Y; Huang L; Tao L; Chen J; Li J
Front Oncol; 2023; 13():1169876. PubMed ID: 37152007
[TBL] [Abstract][Full Text] [Related]
6. Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer.
Zeng L; Li Y; Xiao L; Xiong Y; Liu L; Jiang W; Heng J; Qu J; Yang N; Zhang Y
Onco Targets Ther; 2018; 11():6937-6945. PubMed ID: 30410351
[TBL] [Abstract][Full Text] [Related]
7. A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma.
Lan S; Li H; Liu Y; Xu J; Huang Z; Yan S; Zhang Q; Cheng Y
Onco Targets Ther; 2020; 13():11499-11504. PubMed ID: 33204104
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Detection of Double ROS1 Translocations,
Xu L; Chen X; Huo H; Liu Y; Yang X; Gu D; Yuan M; Zhang M; Chen R; Wang J; Zheng Z
Front Med (Lausanne); 2021; 8():649177. PubMed ID: 34616749
[No Abstract] [Full Text] [Related]
9. Case report: A novel reciprocal ROS1-CD74 fusion in a NSCLC patient partially benefited from sequential tyrosine kinase inhibitors treatment.
Zhang X; Wang B; Wang C; Liao C; Wang S; Cao R; Ma T; Wang K
Front Oncol; 2022; 12():1021342. PubMed ID: 36387218
[TBL] [Abstract][Full Text] [Related]
10. Incidence of
Mehta A; Saifi M; Batra U; Suryavanshi M; Gupta K
Lung Cancer (Auckl); 2020; 11():19-25. PubMed ID: 32158297
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
[TBL] [Abstract][Full Text] [Related]
12. CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.
Zhu YC; Zhou YF; Wang WX; Xu CW; Zhuang W; Du KQ; Chen G
Thorac Cancer; 2018 May; 9(5):652-655. PubMed ID: 29517860
[TBL] [Abstract][Full Text] [Related]
13. Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel
Chen AG; Chen DS; Li S; Zhao LL; Xiao MZ
Front Oncol; 2022; 12():837219. PubMed ID: 35299735
[TBL] [Abstract][Full Text] [Related]
14. Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report.
Dong D; Shen G; Da Y; Zhou M; Yang G; Yuan M; Chen R
Oncologist; 2020 Nov; 25(11):e1720-e1724. PubMed ID: 32652753
[TBL] [Abstract][Full Text] [Related]
15. Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
Wang Y; Chen Z; Han X; Li J; Guo H; Shi J
Oncologist; 2021 Mar; 26(3):178-181. PubMed ID: 33000474
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
Capizzi E; Dall'Olio FG; Gruppioni E; Sperandi F; Altimari A; Giunchi F; Fiorentino M; Ardizzoni A
Lung Cancer; 2019 Sep; 135():88-91. PubMed ID: 31447007
[TBL] [Abstract][Full Text] [Related]
17.
Cheng Y; Yang J; Wang D; Yan D
Ann Transl Med; 2022 Feb; 10(3):157. PubMed ID: 35284560
[No Abstract] [Full Text] [Related]
18. Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with
Zhu YC; Zhang XG; Lin XP; Wang WX; Li XF; Wu LX; Chen HF; Xu CW; Du KQ
Oncol Lett; 2019 Mar; 17(3):3466-3474. PubMed ID: 30867785
[TBL] [Abstract][Full Text] [Related]
19. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
[TBL] [Abstract][Full Text] [Related]
20. A novel co-existing
Zhu YC; Wang WX; Xu CW; Zhuang W; Song ZB; Du KQ; Chen G; Lv TF; Song Y
Cancer Biol Ther; 2018; 19(12):1097-1101. PubMed ID: 30095326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]